Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients

Patients with relapsed or refractory acute myeloid leukemia (RR-AML) with mutations of FMS-like tyrosine kinase 3 (FLT3) have a poor prognosis even after allogeneic hematopoietic cell transplantation (allo-HCT). Multiple FLT3 inhibitors, including gilteritinib, have been developed and serve as treat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood cell therapy 2023-08, Vol.6 (3), p.77-79
Hauptverfasser:	Mima, Fuka, Fuji, Shigeo, Shibata, Kumi, Kida, Shuhei, Tsutsumi, Kazuhito, Tada, Yuma, Shingai, Yasuhiro, Yuda, Sayako, Yokota, Takafumi, Ishikawa, Jun
Format:	Artikel
Sprache:	eng
Schlagworte:	Case Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!